Prevail Therapeutics

Prevail Therapeutics, a company based in New York City, is a subsidiary of Eli Lilly and Company. Founded in 2017, the company focuses its efforts on developing novel gene therapies to address the root genetic causes of Parkinson's disease and other neurodegenerative disorders. With 32 employees, Prevail Therapeutics has generated approximately $50 million in revenue. The company's therapies aim to slow or halt the progression of these debilitating diseases. They utilize a precision medicine approach, targeting specific patient populations with urgent needs where existing therapies are insufficient to modify the course of their conditions. Prevail Therapeutics emphasizes its commitment to scientific rigor, collaboration, integrity, and agility. The company prides itself on building a team of dedicated and talented individuals who share their passion for serving patients with neurodegenerative diseases. For more information, please visit the Eli Lilly and Company website at www.lilly.com.